← All trials
NCT04796636
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2021
- Primary completion
- Sep 22, 2022
- Completion date
- Dec 22, 2022
- First posted
- Mar 15, 2021
- Last posted
- Oct 28, 2021
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Melbourne HealthLead sponsor
- University of MelbourneCollaborator
- Melbourne HealthOverall official - principal investigator
- The Florey Institute of Neuroscience and Mental HealthCollaborator
- Monash UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.